Abstract
Background: It is still controversial to employ osimertinib as the first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients in practice. The aim of the current study was to explore the risk factors of acquired T790M mutation during EGFR-TKIs therapy, and to identify the potential patients most likely to benefit from first-line osimertinib treatment.
Methods: A total of 222 patients with EGFR-mutated (non-T790M) advanced NSCLC were analyzed. The progression-free survival (PFS), overall survival (OS), and cumulative incidence of acquired T790M mutation were calculated with the Kaplan-Meier method. The independent risk factors were investigated with the multivariate analysis.
Results: A total of 70 patients acquired T790M mutation and were treated with osimertinib as a second-line treatment. These patients showed a significantly better OS (P=0.003) than those without T790M mutation. Multivariate analysis indicated that BMI ≤ 25 (P= 0.031), NSE > 17.9 ng/ml (P= 0.013) before treatment, and retroperitoneal lymph node (LN) metastasis (P= 0.002) were independent risk factors of acquired T790M mutation. At last, the actuarial risks of acquired T790M mutation at 1 year after EGFR-TKI treatment were 6.6% in patients with 0-1 risk factor and 31.5% in patients with 2-3 risk factors.
Conclusions: Patients developing acquired T790M mutation during EGFR-TKI treatment had a better OS of osimertinib treatment. Lower BMI, higher NSE before treatment, and retroperitoneal LN metastasis are independent risk factors of acquired T790M mutation. Our study suggested that patients with 2-3 risk factors were highly recommended the first-line osimertinib treatment.
Keywords: non-small cell lung cancer, epidermal growth factor receptor, T790M, tyrosine kinase inhibitor, risk factors
Introduction
Epidermal growth factor receptor (EGFR) mutations are observed in approximately 10-15% of the Caucasian population 1 and more than 50% of the Asian population 2 with non-squamous non-small cell lung cancer (NSCLC). It is well known that these patients can be treated with first-generation or second-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, or afatinib 3,4. However, acquired resistance is almost inevitable after a median treatment period of 9-13 months 5. The acquired p.Thr790Met (T790M) point mutation 6-8 accounts for 50-60% resistance to the first- or second-generation EGFR-TKIs regardless of race or ethnic background 8-11. Osimertinib is an oral and irreversible third-generation EGFR-TKI, selective for EGFR mutations including exon 19 deletion, L858R, and T790M mutation 12-14. Based on the results of the AURA clinical program 15-17, osimertinib was approved worldwide to treat metastatic NSCLC patients with T790M mutation who have disease progression during or after EGFR-TKIs therapy.
Recently, the FLAURA study showed an impressive progression free survival (PFS) benefit of osimertinib against gefitinib (18.9 VS.10.2 months) 18, resulting in approval of osimertinib as the first-line treatment for patients with EGFR-mutated advanced NSCLC regardless of T790M mutation status. However, the median overall survival (OS) benefit of osimertinib against gefitinib in FLAURA study does not appear satisfactory (38.6 VS.31.8 months). And some argued that the sequential EGFR-TKIs treatment might not be inferior to the first-line osimertinib treatment in patients who will develop acquired T790M mutation. Moreover, the currently mechanisms of acquired resistance to osimertinib is unclear for clinical treatment. There would be no subsequent EGFR-TKIs treatment except chemotherapy for the patients who progressed after first-line osimertinib treatment. In addition, the first-generation EGFR-TKIs in combination with antiangiogenic agents (bevacizumab, ramucirumab) 19-21 or chemotherapy 22,23 might be a promising treatment for providing a favorable PFS and even OS. For example, in the NEJ009 study, the first-generation EGFR-TKIs combined with chemotherapy could bring a OS of up to 52.2 months. Considering the cost of osimertinib versus the first/second-generation EGFR-TKIs, the first-line osimertinib treatment is still not widely available.
The AURA clinical program 15-17 confirms that osimertinib treatment can prolong the survival of patients with acquired T790M mutated NSCLC 15. In FLAURA study, upfront osimertinib showed better outcomes than the first-line treatment of gefitinib. According to previous studies, only 50-60% EGFR-mutated patients would develop acquired T790M mutation 8-11. Meanwhile, post-study treatment data of FLAURA study reported in ESMO 2019 showed that 95% patients had disease progression in the gefitinib arm, whereas only 30.55% patients could receive osimertinib as the second-line therapy (65% patients received the second-line therapy, of which 47% received osimertinib). The possible reason was some patients who progressed in gefitinib arm might experience PS score decline, or the second biopsies might be not feasible. Therefore, for patients who will develop T790M mutation, these results indirect suggested that the first-line usage of osimertinib would be more beneficial than the sequential EGFR-TKIs treatments. To date, there is no effective method to screen out these patients.
Consequently, this finding prompted us to identify the population subset that is at the highest risk of developing acquired T790M mutation. We established a retrospective single-institutional database including consecutive patients with EGFR-mutated advanced NSCLC between January 2012 and June 2018, to explore the possible risk factors of acquired T790M mutation during first-generation EGFR-TKI treatment. Our study provided effective methods to screen out the patients who are most likely to benefit from the first-line osimertinib treatment.
Patients and Methods
Patients
Between January 2012 and June 2018, A total of 229 consecutive patients with EGFR-mutated advanced NSCLC were treated at the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University. Among the 229 patients, 4 were excluded due to intrinsic T790M mutation, and 3 were excluded due to short EGFR-TKI treatment (≤ 1 month). A total of 222 eligible patients were included in this study. Our inclusion criteria were: (1) NSCLC was confirmed by cytology (17 pts) or histology (205 pts) (World Health Organization, WHO); (2) The patients were clinically diagnosed as stage IIIB (10 pts) or IV (212 pts) (American Joint Committee on Cancer, the 7th Edition); (3) The patients were treatment naive for EGFR-TKI treatment; (4) Initial EGFR mutations were confirmed by real-time fluorescent quantitative PCR (184 pts, ARMS PCR, Amoy Diagnostics Co., Ltd) or Next Generation Sequencing (38 pts, NGS, Amoy Diagnostics Co., Ltd), using histological or cytological specimens from primary or metastatic lesions; (5) The initial EGFR mutations did not contain the concomitant mutation of T790M. All patients received comprehensive assessments within 1 month before treatment, including physical and pathological examination, EGFR mutation test, and TNM stage evaluation. The clinical and treatment characteristics were shown in Table 1.
Table 1.
Clinical characteristics of patients
| Characteristic | NO. | % |
|---|---|---|
| NO. of all patients with EGFR mutations | 226 | |
| NO. of patients with intrinsic T790M mutation | 4 | 1.8 |
| NO. of patients developing T790M mutation | 70 | 31.0 |
| Age, years | 222 | |
| Median(Range) | 57(30-93) | |
| Gender | 222 | |
| Male | 97 | 43.7 |
| Female | 125 | 56.3 |
| KPS score | 222 | |
| ≥80 | 199 | 89.6 |
| <80 | 23 | 10.4 |
| Histology | 222 | |
| Adenocarcinoma | 214 | 96.4 |
| Non-adenocarcinoma carcinoma | 8 | 3.6 |
| BMI | 219 | |
| ≤25 | 184 | 84.0 |
| >25 | 35 | 16.0 |
| Median(Range) | 21.91(13.67-30.82) | |
| Smoking status | 222 | |
| Yes | 62 | 27.9 |
| No | 160 | 72.1 |
| CEA (ng/ml) | 196 | |
| >25.4 | 98 | 50.0 |
| ≤25.4 | 98 | 50.0 |
| Median(Range) | 27.23 (0.61-8048.83) | |
| CA125 (ng/ml) | 176 | |
| Median(Range) | 48.08 (4.76-5304.00) | |
| NSE(ng/ml) | 176 | |
| >17.9 | 62 | 35.2 |
| ≤17.9 | 114 | 64.8 |
| Median(Range) | 14.61 (4.42-70.87) | |
| First-line treatment regimen | 222 | |
| EGFR-TKI treatment | 195 | 87.8 |
| Chemotherapy | 27 | 12.2 |
| The intervention of radiotherapy or not | 222 | |
| NO. of radiotherapy for oligometastatic metastases | 36 | 16.2 |
| NO. of radiotherapy for oligoprogressive metastases | 43 | 19.4 |
| Type of EGFR mutations | 222 | |
| Exon 21 point mutation | 94 | 42.3 |
| Exon 19 deletion mutation | 119 | 52.7 |
| Other | 11 | 5.0 |
| NO. of metastasis | 222 | |
| 0 | 10 | 4.5 |
| 1 | 103 | 46.4 |
| 2 | 74 | 33.3 |
| 3 or more | 35 | 15.8 |
| Location of metastatic sites | 222 | |
| Brain | 71 | 32.0 |
| Pleural effusion | 18 | 8.1 |
| Liver | 25 | 11.3 |
| Adrenal | 28 | 12.6 |
| Bone | 116 | 52.3 |
| Lung | 123 | 55.4 |
| Retroperitoneal LN | 14 | 6.3 |
| Other | 6 | 2.7 |
| Type of EGFR-TKIs | 222 | |
| Gefitinib | 178 | 80.2 |
| Erlotinib | 15 | 6.8 |
| Icotinib | 29 | 13.1 |
| Type of post-progression confirmed gene testing | 159 | |
| Tissue | 46 | 28.9 |
| Cellular | 9 | 5.7 |
| Plasma | 104 | 65.4 |
This retrospective study was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University. Ethics Committee approved oral informed consent, as the data were reviewed and analyzed anonymously. Informed consent was obtained orally from the included patients by telephone.
Treatment and Follow up
There were 27 patients receiving chemotherapy as the first-line treatment, and the other 195 patients receiving the first-generation EGFR-TKI (gefitinib, erlotinib, or icotinib) treatment initially, with or without radiotherapy. For EGFR-TKIs treatment, was continuously administered, until progression of disease (PD) or intolerable side effects. Treatment beyond disease progression was allowed if the oncologist judged continued clinical benefit. Follow-up examinations were performed every 2 months, including thoracic and abdominal CT scan and brain MRI scan, until death or loss of follow-up. Treatment response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including complete response (CR), partial response (PR), stable disease (SD), and PD. PFS was defined as the time from EGFR-TKI treatment to PD (local, regional, or distant progression) or death from any cause. Time to subsequent treatment (TTST) was defined as the time from EGFR-TKI treatment to subsequent treatment or death from any cause. OS was defined as time from the first-generation EGFR-TKI treatment to death from any cause. OStotal was defined as time from diagnosis to death from any cause. T790M-developing-free survival (TDFS) was defined as time from the first-generation EGFR-TKI treatment to the occurence of documented post-progression T790M mutation.
Statistics
All statistical analyses were conducted using Statistical Package for Social Scientists (SPSS Version 22.0, SPSS Inc., Chicago, USA). Descriptive statistics were used for categorical variables (frequency and percentage) and continuous variables (median and range). The cumulative incidence of acquired T790M mutation and survival were calculated by the Kaplan-Meier method with 95% confidence interval (CI). Univariable and multivariable Cox regression analyses were performed to analyze the risk factors of acquired T790M mutation. The multivariable Cox regression analysis simultaneously included factors that had shown associations (P < 0.100) in the univariable Cox regression analyses. In addition, patients were stratified into 2 risk groups according to the independent risk factors of multivariable Cox regression analysis. Log-rank survival analysis was performed to examine the difference of survival between these 2 groups. The optimal cut-off values of continuous valuables were calculated by X-tile software 24. All tests were two-sided and P < 0.05 were considered statistically significant.
Results
Patient characteristics
A total of 229 consecutive patients with EGFR-mutated advanced NSCLC were analyzed. Except 4 patients with intrinsic T790M mutation, and 3 with short EGFR-TKI treatment (< 1 month), 222 eligible patients were enrolled in this retrospective study. Among them, 70 patients acquired T790M mutation during the EGFR-TKI treatment and received third-generation EGFR-TKI therapy, whose T790M mutation were confirmed in plasma (51 pts, ddPCR, KingMed Diagnostics Group Co., Ltd.), cellular (3 pts, ddPCR, KingMed Diagnostics Group Co., Ltd.) or tissue (16 pts, NGS, Genecast Biotechnology Co., Ltd) specimens. All of the 222 patients were analyzed for the risk factors of acquired T790M mutation by univariable and multivariable Cox regression analyses.
Acquired T790M mutation indicates better outcomes
The median duration of follow-up was 22.8 months (95% CI: 19.3-26.2 months). The median OS of the 222 patients was 37.5 months (95% CI: 26.9-48.1 months). The OS rates of 1-year, 2-year, and 3-year were 88.3%, 64.2%, and 53.4% respectively. The median OStotal of the 222 patients was also 37.5 months (95% CI: 27.7-47.3 months). The OStotal rates of 1-year, 2-year, and 3-year were 89.0%, 65.4%, and 55.1% respectively.
To evaluate the effect of acquired T790M mutation on OS, Log-rank comparisons of OS were performed based on T790M mutation status. Patients with acquired T790M mutation had better outcomes (median OS: 48.3 months, median OStotal: 59.1 months) than patients without T790M mutation (median OS: 26.8 months, median OStotal: 30.3 months). The survival curves were shown in Fig.1. Our median OS was longer than those of previous clinical trials of EGFR-TKI treatment for EGFR-mutated advanced NSCLC patients 25, which was largely attributed to the usage of osimertinib.
Figure 1.
Kaplan-Meier plot of OS (A) and OStotal (B) in EGFR-mutated advanced NSCLC patients with or without acquired T790M mutation. OS, overall survival from the first-generation EGFR-TKI treatment; OStotal, overall survival from initial treatment (the first-generation EGFR-TKI treatment or chemotherapy): CI, confidence interval.
Acquired T790M mutation had no impact on PFS
The median PFS of the 222 patients was 12.4 months (95% CI: 11.3-13.6 months). The PFS rates of 1-year, 2-year, and 3-year were 51.7%, 17.1%, and 10.3% respectively (Fig. 2A). A total of 159 patients (71.6%) had PD for the first time during follow-up period. Among them, the number of patients with local progression, slow progression, and rapid progression was 73 (45.9%), 39 (24.5%), and 47 (29.6%) respectively. In addition, the median PFS of patients with acquired T790M mutation was 12.5 months (95% CI: 11.0-14.0 months), and the median PFS of patients without T790M mutation was 12.2 months (95% CI: 10.4-14.0 months) (Fig. 2A). The acquired T790M mutation did not significantly influence on the PFS of the first-generation EGFR-TKIs therapy (P = 0.077).
Figure 2.
Kaplan-Meier plot of PFS (A) and TTST (B) in EGFR-mutated advanced NSCLC patients with or without acquired T790M mutation. PFS, progression-free survival from the EGFR-TKI treatment to PD or death; TTST, time to subsequent treatment from the EGFR-TKI treatment to subsequent treatment or death; CI, confidence interval.
Furthermore, EGFR-TKIs treatment beyond disease progression was allowed if the oncologist judged continued clinical benefit. Therefore, 82 patients (82/159, 51.6%) with local progression or slow progression received continuous the first-generation EGFR-TKIs treatment with or without radiotherapy. Whereas, 26 patients (16.4%) switched to chemotherapy, 35 patients (22%) switched to the third-generation EGFR-TKIs, and 16 patients (10.1%) received supportive care. The median TTST of the 222 patients was 16.0 months (95% CI: 14.6-17.4 months). While the median TTST of the patients with acquired T790M mutation was 14.9 months (95% CI: 12.9-17.0 months), and the median TTST of patients without T790M mutation was 19.2 months (95% CI: 14.7-23.6 months) (Fig. 2B). The duration of first-generation EGFR-TKI treatment for the patients without T790M mutation was significantly longer than that for the patients with acquired T790M mutation (P = 0.000, Fig. 2B). It was largely attributed to the intervention of radiotherapy for oligometastatic (9 pts developed acquired T790M mutation, and 27 pts didn't develop acquired T790M mutation) and oligoprogressive (14 pts developed acquired T790M mutation, and 29 pts didn't develop acquired T790M mutation) metastases in patients during the EGFR-TKIs treatments.
The incidence of acquired T790M mutation and post-treatment
Between January 2012 and June 2018, 159 patients had PD for the first time. All of them firstly received the detection of T790M mutation by droplet digital PCR (ddPCR, KingMed Diagnostics Group Co., Ltd.) using plasma specimens. Among them, 51 patients were confirmed T790M mutation. Then 46 patients with plasma T790M mutation negative received tissue rebiopsy for T790M mutation detection by NGS (16 pts confirmed T790M mutation, Genecast Biotechnology Co., Ltd), and the malignant pleural effusion of 9 patients were detected by ddPCR (3 pts confirmed T790M mutation, KingMed Diagnostics Group Co., Ltd.). A total of 70 patients were confirmed to develop acquired T790M mutation during the EGFR-TKI treatment. The positive rate of acquired T790M mutation was 44.0%, which was consistent with previous studies 8-11. The median TDFS was 24.9 months (95% CI: 21.9-27.9 months), and the risk of developing acquired T790M mutation at 1-year, 2-year, and 3-year was 12.1%, 45.3%, and 66.3% respectively (Fig. 3A).
Figure 3.
(A) Kaplan-Meier plot of acquired T790M mutation risks in patients with EGFR-mutated advanced NSCLC. (B) Kaplan-Meier plot of PFS in T790M-mutated patients treated with osimertinib. PFS, progression-free survival from osimertinib treatment to PD or death; CI, confidence interval.
All of the 70 patients with acquired T790M mutation received subsequent therapy of the third-generation EGFR-TKI (osimertinib). The median duration of osimertinib treatment was 15.2 months (95% CI: 8.0-22.3 months) (Fig. 3B). On account of the intervention of radiotherapy for oligoprogressive metastases during osimertinib treatment, our results of the median duration of osimertinib treatment were longer than PFS of the AURA3 study for advanced NSCLC patients with T790M mutation in osimertinib subsequent-line therapy 15.
Risk factors of developing acquired T790M mutation
In univariate analyses, the lower BMI of patients, higher CEA and NSE level before treatment, liver metastasis, bone metastasis, and retroperitoneal lymph node (LN) metastasis were associated with increased risks of acquired T790M mutation. No significant association was found between acquired T790M mutation and other factors, such as gender, age, KPS score, smoking status, CA125 level before treatment, first-line treatment regimen, intervention of radiotherapy, type of EGFR mutations at initial diagnosis, and other location of metastatic sites (Table 2).
Table 2.
Univariate analyses for the risk factors of developing T790M mutation
| Factors | HR | 95%CI | P |
|---|---|---|---|
| Gender: female VS male | 1.449 | 0.894-2.348 | 0.132 |
| Age, years | 0.994 | 0.971-1.017 | 0.587 |
| KPS score: <80 VS ≥80 | 1.422 | 0.612-3.304 | 0.414 |
| BMI | 0.932 | 0.877-0.990 | 0.023 |
| >25 VS ≤25 | 0.371 | 0.169-0.815 | 0.014 |
| Smoking: yes VS no | 0.873 | 0.515-1.480 | 0.614 |
| Tumor markers level before treatment | |||
| CEA (ng/ml) | 1.000 | 1.000-1.000 | 0.011 |
| >25.4VS ≤25.4 | 2.006 | 1.190-3.381 | 0.009 |
| CA125 (ng/ml) | 1.000 | 1.000-1.001 | 0.107 |
| NSE (ng/ml) | 1.020 | 0.999-1.043 | 0.057 |
| >17.9 VS ≤17.9 | 2.135 | 1.221-3.731 | 0.008 |
| First-line treatment regimen | |||
| Chemotherapy VS EGFR-TKI | 1.083 | 0.569-2.064 | 0.808 |
| The intervention of radiotherapy or not (Yes VS No) | |||
| Radiotherapy for oligometastatic metastases | 0.954 | 0.473-1.923 | 0.894 |
| Radiotherapy for oligoprogressive metastases | 0.415 | 0.151-1.140 | 0.088 |
| Type of EGFR mutations | 0.436 | ||
| 19-del VS L858R | 1.326 | 0.806-2.184 | 0.267 |
| Other VS L858R | 1.673 | 0.576-4.857 | 0.344 |
| NO. of metastasis | 0.298 | ||
| ≤1 VS 3 or more | 0.651 | 0.299-1.417 | 0.279 |
| 2 VS 3 or more | 0.931 | 0.420-2.062 | 0.860 |
| Location of metastasis | |||
| Brain | 0.909 | 0.531-1.557 | 0.728 |
| Pleural effusion | 0.788 | 0.286-2.170 | 0.645 |
| Liver | 2.016 | 1.025-3.964 | 0.042 |
| Adrenal | 0.506 | 0.203-1.260 | 0.143 |
| Bone | 1.516 | 0.941-2.442 | 0.088 |
| Lung | 1.084 | 0.675-1.743 | 0.738 |
| Retroperitoneal LN | 3.698 | 1.809-7.560 | 0.000 |
| Other | 0.047 | 0.000-17.343 | 0.310 |
The multivariable analysis simultaneously included factors that had shown associations (P < 0.100) in the univariable analyses. The results indicated that BMI ≤ 25 (P = 0.031), NSE > 17.9 ng/ml before treatment (P = 0.013) and retroperitoneal LN metastasis (P = 0.002) were the independent risk factors of acquired T790M mutation. Whereas, liver metastasis, bone metastasis, and CEA levels before treatment were not significantly associated with acquired T790M mutation (Fig. 4).
Figure 4.
Multivariate analysis and forest plots indicate the independent risk factors of acquired T790M mutation. HR, hazard ratio; CI, confidence interval.
Furthermore, patients were stratified into 2 risk subgroups: patients with 0~1 (n = 167) risk factor as the low-risk group, and patients with 2~3 (n = 55) risk factors as the high-risk group. The actuarial risk of developing acquired T790M mutation at 1 year were 6.6% in the low-risk group and 31.5% in the high-risk group (P = 0.001, Fig. 5). Obviously, patients with 2~3 risk factors had a higher risk of developing acquired T790M mutation. Our studies suggested that the patients with 2~3 risk factors were candidates for the third-generation EGFR-TKIs as the first-line therapy.
Figure 5.
Comparison of the actuarial risk of acquired T790M mutation among patients with different numbers of risk factors.
Discussion
Before the approval of EGFR-TKIs, the median OS of advanced NSCLC patient was no more than 1 year 26. Whereas the discovery and advances of EGFR-TKIs revolutionarily improved prognosis of EGFR-mutated advanced NSCLC patients. The clinical trials of the first- or second-generation EGFR-TKIs showed a median OS of 19.3-33.2 months 25,27. Similarly, osimertinib, as one of the third-generation EGFR-TKIs that selectively inhibit T790M mutation 14, significantly improves the survival of patients with T790M mutation 15-17. Our study firstly evaluated the effect of acquired T790M mutation on OS. The patients without T790M mutation had a significantly higher risk of OS compared with the patients with acquired T790M mutation. In detail, our median OS of the 222 patients with EGFR-mutated advanced NSCLC was 37.5 months (95% CI: 26.9-48.1 months). Patients with acquired T790M mutation showed a median OS of 48.3 months (95% CI:28.4-68.1 months) (Fig.1). The better OS in our study than the first-generation EGFR-TKIs clinical trials 25 was attributed to the usage of third-generation EGFR-TKIs for patients with acquired T790M mutation. Therefore, our results also confirmed that the OS of patients with acquired T790M mutation was prolonged by the usage of osimertinib.
Moreover, the median PFS of the 222 patients was 12.4 months, and there was no difference in PFS of the first-generation EGFR-TKIs treatment between patients with acquired T790M mutation group and without T790M mutation group (P = 0.077). Our result of median PFS is consistent with the results of the first-generation EGFR-TKIs clinical trials 25. Whereas the median TTST for patients without T790M mutation was 19.2 months, while 14.9 months (P = 0.000, Fig.2B) for patients with acquired T790M mutation. It was largely attributed to the intervention of radiotherapy for oligometastatic and oligoprogressive metastases in patients during the EGFR-TKIs treatments, especially for patients without T790M mutation. Our results also confirmed the important role of radiotherapy in the management of EGFR-mutated advanced NSCLC patients.
Between January 2012 and June 2018, 159 patients had PD for the first time and were detected for T790M mutation. A total of 70 patients were documented to acquire T790M mutation. The positive rate of T790M mutation was 44.0%, which was consistent with previous reports 8-11. All of 70 patients with acquired T790M mutation received subsequent osimertinib treatment. The median duration of osimertinib treatment was 15.2 months (95% CI: 8.0-22.3 months) (Fig.3B). The subgroup analysis of the AURA3 study in Japanese patients showed a median PFS of 12.5 months 15. Considering the intervention of radiotherapy for oligoprogressive metastases, our results of the median duration of osimertinib treatment was still consistent.
The FLAURA study shows PFS benefit in the third-generation EGFR-TKI osimertinib than the first-generation EGFR-TKI gefitinib for the first line treatment 18. But considering the cost-effectiveness of osimertinib, the first-line osimertinib treatment for EGFR-mutated advanced NSCLC patients is still not widely available. In our study, there were 159 patients who had PD for the first time during follow-up period, and 53 patients just confirmed plasma T790M mutation negative. Among them, 16 patients had poor performance status, and 17 patients refused the second biopsy, and the lesions of 20 patients are not suitable for rebiopsy. Therefore, on account of some patients who progressed after first/second-generation EGFR-TKIs treatment might have poor performance status, or the second biopsies might be not feasible. At least for patients who would develop acquired T790M mutation, it was strongly recommended the osimertinib first-line treatment rather than the sequential EGFR-TKIs treatments. In order to identify the population subset with higher risk of developing acquired T790M mutation, we performed multivariate Cox regression analysis. Our results indicated that BMI ≤ 25, NSE > 17.9ng/ml before treatment and retroperitoneal LN metastasis were the independent risk factors of developing acquired T790M mutation. To date, there have been no study to explain the underlying mechanisms of the correlation between these risk factors and acquired T790M mutation. The mechanisms are still to be investigated. Furthermore, patients were divided into 2 risk subgroups: patients with 0~1 (n=167) risk factors of low-risk group, and patients with 2~3 (n=55) risk factors of high-risk group. The actuarial risk of developing acquired T790M mutation at 1 year were 6.6% in the low-risk group and 31.5% in the high-risk group. Our study suggested that the patients with 2~3 risk factors were potential candidates for the third-generation EGFR-TKIs as the first-line therapy.
At last, our findings confirmed that the third-generation EGFR-TKI improved the survival of patients with acquired T790M mutation. Lower BMI (≤ 25), higher NSE (> 17.9 ng/ml) before treatment and retroperitoneal LN metastasis were the independent risk factors of acquired T790M mutation. Certainly, there are several limitations in our study, this was a retrospective study in a single institution, which inevitably resulted in a selection bias. The feasibility of selectively using osimertinib as first-line treatment in higher-risk patients should be further confirmed in the future, and the mechanisms of the correlation between these risk factors and acquired T790M mutation is to be explored. However, we firstly presented the view that using osimertinib as first-line treatment in higher-risk patients, which is the theoretical innovation part of this paper. As well as IPASS study, the better biomarkers will be found to predict for acquired T790M mutation by the exploration of risk factors.
Acknowledgments
This study was supported by National Natural Science Foundation of China (81502308 and 81773236).
Author Contributions
Conception and design of the work: Wen Ouyang, Conghua Xie. Acquisition, analysis and interpretation of data: Wen Ouyang, Jing Yu, Zhao Huang, Gang Chen, Yu Liu, Zhengkai Liao, Wei Zeng, Junhong Zhang. Drafting the work and revising it: Wen Ouyang, Jing Yu, Conghua Xie. Final approval of the final version and agreement to be accountable for all aspects of the work: all authors.
References
- 1.Barlesi F, Mazieres J, Merlio JP. et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Lancet. 2016;387(10026):1415–1426. doi: 10.1016/S0140-6736(16)00004-0. [DOI] [PubMed] [Google Scholar]
- 2.Mok TS, Wu YL, Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699. [DOI] [PubMed] [Google Scholar]
- 3.Hanna N, Johnson D, Temin S. et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(30):3484–3515. doi: 10.1200/JCO.2017.74.6065. [DOI] [PubMed] [Google Scholar]
- 4.Planchard D, Popat S, Kerr K. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 doi: 10.1093/annonc/mdy275. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- 5.Suda K, Mizuuchi H, Maehara Y. et al. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev. 2012;31(3-4):807–814. doi: 10.1007/s10555-012-9391-7. [DOI] [PubMed] [Google Scholar]
- 6.Wu SG, Liu YN, Tsai MF. et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7(11):12404–12413. doi: 10.18632/oncotarget.7189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Campo M, Gerber D, Gainor JF. et al. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016;11(11):2022–2026. doi: 10.1016/j.jtho.2016.06.032. [DOI] [PubMed] [Google Scholar]
- 8.Yu HA, Arcila ME, Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi: 10.1158/1078-0432.CCR-12-2246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kobayashi S, Boggon TJ, Dayaram T. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792. doi: 10.1056/NEJMoa044238. [DOI] [PubMed] [Google Scholar]
- 10.Sequist LV, Waltman BA, Dias-Santagata D. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi: 10.1126/scitranslmed.3002003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Oxnard GR, Arcila ME, Sima CS. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616–1622. doi: 10.1158/1078-0432.CCR-10-2692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cross DA, Ashton SE, Ghiorghiu S. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061. doi: 10.1158/2159-8290.CD-14-0337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ballard P, Yates JW, Yang Z. et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22(20):5130–5140. doi: 10.1158/1078-0432.CCR-16-0399. [DOI] [PubMed] [Google Scholar]
- 14.Vansteenkiste J, Reungwetwattana T, Nakagawa K, CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Ann Oncol; 2017. p. 28. (suppl_10) [Google Scholar]
- 15.Mok TS, Wu Y-L, Ahn M-J. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–640. doi: 10.1056/NEJMoa1612674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Goss G, Tsai CM, Shepherd FA. et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652. doi: 10.1016/S1470-2045(16)30508-3. [DOI] [PubMed] [Google Scholar]
- 17.Yang JC, Ahn MJ, Kim DW. et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017;35(12):1288–1296. doi: 10.1200/JCO.2016.70.3223. [DOI] [PubMed] [Google Scholar]
- 18.Soria JC, Ohe Y, Vansteenkiste J. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137. [DOI] [PubMed] [Google Scholar]
- 19.Saito H, Fukuhara T, Furuya N. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635. doi: 10.1016/S1470-2045(19)30035-X. [DOI] [PubMed] [Google Scholar]
- 20.Seto T, Kato T, Nishio M. et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244. doi: 10.1016/S1470-2045(14)70381-X. [DOI] [PubMed] [Google Scholar]
- 21.Reck M, Garon EB, Paz-Ares L. et al. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018;19(3):213–220. doi: 10.1016/j.cllc.2017.11.003. [DOI] [PubMed] [Google Scholar]
- 22.Oizumi S, Sugawara S, Minato K. et al. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Nakamura A, Inoue A, Morita S. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced nonsmall cell lung cancer (NSCLC) with EGFR mutations (NEJ009) J Clin Oncol; 2018. p. 36. (suppl; abstr 9005) [Google Scholar]
- 24.Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi: 10.1158/1078-0432.CCR-04-0713. [DOI] [PubMed] [Google Scholar]
- 25.Roeper J, Griesinger F. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? Curr Opin Oncol. 2019;31(1):1–7. doi: 10.1097/CCO.0000000000000495. [DOI] [PubMed] [Google Scholar]
- 26.Fisher MD, D'Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594) Clin Lung Cancer. 2000;2(1):21–22. [PubMed] [Google Scholar]
- 27.Sebastian M, Niederle N, Thomas M. et al. Molecular genetic tests in advanced non-small cell lung cancer: practical relevance. Dtsch Med Wochenschr. 2014;139(41):2096–2100. doi: 10.1055/s-0034-1387294. [DOI] [PubMed] [Google Scholar]